NEW YORK (GenomeWeb) – Sphere Fluidics will use the proceeds of a new round of funding to support the development of a "industrial" version of its Cyto-Mine single-cell analysis platform that it hopes to place in the R&D laboratories of its growing roster of pharmaceutical industry clients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.